Benjamin F. Edwards & Company Inc. Acquires 596 Shares of GlaxoSmithKline PLC (NYSE:GSK)

Benjamin F. Edwards & Company Inc. increased its stake in GlaxoSmithKline PLC (NYSE:GSK) by 2.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 21,479 shares of the pharmaceutical company’s stock after buying an additional 596 shares during the period. Benjamin F. Edwards & Company Inc.’s holdings in GlaxoSmithKline PLC were worth $926,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. 10 15 Associates Inc. increased its position in GlaxoSmithKline PLC by 6.4% in the first quarter. 10 15 Associates Inc. now owns 237,716 shares of the pharmaceutical company’s stock worth $10,022,000 after buying an additional 14,247 shares in the last quarter. Lincluden Management Ltd. increased its position in GlaxoSmithKline PLC by 1.7% in the first quarter. Lincluden Management Ltd. now owns 120,845 shares of the pharmaceutical company’s stock worth $5,095,000 after buying an additional 1,990 shares in the last quarter. Anchor Capital Advisors LLC increased its position in GlaxoSmithKline PLC by 9.6% in the first quarter. Anchor Capital Advisors LLC now owns 613,324 shares of the pharmaceutical company’s stock worth $25,858,000 after buying an additional 53,894 shares in the last quarter. BlueCrest Capital Management Ltd increased its position in GlaxoSmithKline PLC by 293.5% in the first quarter. BlueCrest Capital Management Ltd now owns 51,157 shares of the pharmaceutical company’s stock worth $2,157,000 after buying an additional 38,157 shares in the last quarter. Finally, Roundview Capital LLC increased its position in GlaxoSmithKline PLC by 157.4% in the first quarter. Roundview Capital LLC now owns 24,529 shares of the pharmaceutical company’s stock worth $1,034,000 after buying an additional 15,000 shares in the last quarter. Institutional investors and hedge funds own 8.99% of the company’s stock.

GlaxoSmithKline PLC (NYSE GSK) opened at 38.75 on Friday. The company has a 50-day moving average price of $41.15 and a 200-day moving average price of $41.84. GlaxoSmithKline PLC has a one year low of $37.20 and a one year high of $44.54. The firm has a market cap of $94.71 billion, a PE ratio of 37.48 and a beta of 1.03.

GlaxoSmithKline PLC (NYSE:GSK) last posted its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.68 by $0.02. The firm had revenue of $9.36 billion during the quarter, compared to the consensus estimate of $9.52 billion. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. Equities analysts predict that GlaxoSmithKline PLC will post $2.85 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Stockholders of record on Friday, August 11th will be issued a dividend of $0.491 per share. This represents a $1.96 dividend on an annualized basis and a dividend yield of 5.07%. The ex-dividend date of this dividend is Wednesday, August 9th. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s dividend payout ratio is 197.00%.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by BNB Daily and is the sole property of of BNB Daily. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.baseball-news-blog.com/2017/08/19/benjamin-f-edwards-company-inc-has-926000-position-in-glaxosmithkline-plc-nysegsk-updated-updated.html.

A number of analysts have weighed in on GSK shares. Zacks Investment Research downgraded GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Friday, July 21st. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Monday, July 24th. BidaskClub downgraded GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. ValuEngine downgraded GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Berenberg Bank raised GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research report on Friday, May 26th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the stock. GlaxoSmithKline PLC has a consensus rating of “Hold” and an average target price of $44.67.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply